<DOC>
	<DOC>NCT00795145</DOC>
	<brief_summary>The FDA has asked Pfizer to assess the risk of linezolid on QT interval (obtained from ECG readings) which could predispose patients to ventricular arrhythmias. This study is conducted to satisfy this requirement.</brief_summary>
	<brief_title>A Study To Assess The Effect Of Linezolid On QTc Interval</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy male and female subjects between the ages of 21 and 55 years. Body mass Index (BMI) of 18 to 30 kg/m2; and a total body weight &gt; 45 kg (99 lbs). An informed consent document signed and dated. Evidence or history of clinically significant abnormality. 12lead ECG demonstrating QTc &gt;450 msec at Screening. Receiving selective serotonin reuptake inhibitors (SSRIs) and/or sympathomimetic agents. Abnormal liver function tests. A positive urine drug screen, history of excessive alcohol and tobacco use.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Linezolid, QTc interval, pharmacokinetics, therapeutic dose, supra-therapeutic dose</keyword>
</DOC>